Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1939 2
1946 1
1947 2
1948 2
1949 4
1950 1
1951 2
1953 1
1954 1
1955 6
1956 6
1957 4
1958 8
1959 3
1960 3
1961 3
1962 5
1963 3
1964 12
1965 10
1966 17
1967 11
1968 3
1969 12
1970 13
1971 12
1972 9
1973 15
1974 13
1975 14
1976 9
1977 8
1978 13
1979 9
1980 8
1981 16
1982 15
1983 15
1984 20
1985 12
1986 22
1987 10
1988 11
1989 4
1990 10
1991 8
1992 9
1993 8
1994 12
1995 9
1996 7
1997 8
1998 4
1999 9
2000 7
2001 6
2002 11
2003 7
2004 14
2005 14
2006 20
2007 14
2008 13
2009 8
2010 9
2011 8
2012 5
2013 15
2014 7
2015 7
2016 14
2017 17
2018 12
2019 13
2020 18
2021 16
2022 6
2023 20
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

715 results

Results by year

Filters applied: . Clear all
Page 1
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR. Miller RE, et al. Ann Oncol. 2020 Dec;31(12):1606-1622. doi: 10.1016/j.annonc.2020.08.2102. Epub 2020 Sep 28. Ann Oncol. 2020. PMID: 33004253 Free article.
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. González-Martín A, et al. Among authors: miller re. Ann Oncol. 2023 Oct;34(10):833-848. doi: 10.1016/j.annonc.2023.07.011. Epub 2023 Aug 17. Ann Oncol. 2023. PMID: 37597580 No abstract available.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Bajrami I, et al. Among authors: miller re. Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15. Cancer Res. 2014. PMID: 24240700 Free PMC article.
Peripheral Mechanisms Contributing to Osteoarthritis Pain.
Syx D, Tran PB, Miller RE, Malfait AM. Syx D, et al. Among authors: miller re. Curr Rheumatol Rep. 2018 Feb 26;20(2):9. doi: 10.1007/s11926-018-0716-6. Curr Rheumatol Rep. 2018. PMID: 29480410 Free PMC article. Review.
Targeted therapies in gynaecological cancers.
Crusz SM, Miller RE. Crusz SM, et al. Among authors: miller re. Histopathology. 2020 Jan;76(1):157-170. doi: 10.1111/his.14009. Histopathology. 2020. PMID: 31846530 Review.
What is new in pain modification in osteoarthritis?
Miller RE, Block JA, Malfait AM. Miller RE, et al. Rheumatology (Oxford). 2018 May 1;57(suppl_4):iv99-iv107. doi: 10.1093/rheumatology/kex522. Rheumatology (Oxford). 2018. PMID: 29361112 Free PMC article. Review.
715 results